Patterson Companies plans to divest non-core product lines in medical segment

theflyonthewall.com

As a result, Patterson will incur a pre-tax restructuring charge in the range of $15M-$17M, or approximately 12c per diluted share, the majority of which will be taken in the second quarter. Divesting these product lines is estimated to generate operational savings of approximately $2M, or 1c per diluted share, beginning in fiscal 2015.

View Comments (0)